Skip to main content

Advertisement

SpringerLink
Log in

Risk of fractures associated with treatment for benign prostate hyperplasia in men

  • Original Article
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

Summary

Treatment of benign prostate hyperplasia with α-blockers may affect blood pressure while treatment with 5-α-reductase inhibitors may affect conversion of testosterone potentially leading to osteoporosis. In our study, neither 5-α-reductase inhibitors nor α-blockers were associated with negative effects on fractures, α-blockers perhaps being associated with a limited decrease in fractures.

Introduction

The objective is to study fracture risk associated with drugs for benign prostate hyperplasia. The hypotheses were that (1) α-blockers may elevate fracture risk by causing presyncope/falls and (2) 5-α-reductase inhibitors may elevate fracture risk by lowering dihydrotestosterone.

Methods

This is a nationwide case-control study using all 9,719 male fracture patients aged ≥60 years in the year 2000 as cases and drawing 29,156 age- and gender-matched controls. The main exposure was the use of the drugs mentioned above for benign prostate hyperplasia. Confounder control included social variables, contacts to hospitals and general practitioners, alcoholism and other variables.

Results

For the 5-α-reductase inhibitors, no change in overall risk of fractures was seen. No change in risk of hip, spine and forearm fractures was present. For the α-blockers, a decrease in overall risk of fractures was seen, as well as a decrease in the risk of hip and spine fractures, but only at average doses >0.5 defined daily doses per day. No decrease was seen for forearm fractures. A decreasing risk of any fracture, hip fractures and spine fractures were seen with increasing dose of α-blockers, while no such association was seen for the forearm fractures.

Conclusion

Neither the 5-α-reductase inhibitors nor α-blockers were associated with negative effects on fracture risk. A small trend towards a decrease in fracture risk may be present for the α-blockers. However, more research is needed to confirm if this trend is real.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bushman W (2009) Etiology, epidemiology, and natural history of benign prostatic hyperplasia. Urol Clin N Am 36:403–415, v

    Article  Google Scholar 

  2. Tollin SR, Rosen HN, Zurowski K, Saltzman B, Zeind AJ, Berg S, Greenspan SL (1996) Finasteride therapy does not alter bone turnover in men with benign prostatic hyperplasia–a Clinical Research Center study. J Clin Endocrinol Metab 81:1031–1034

    Article  CAS  PubMed  Google Scholar 

  3. Djavan B, Chapple C, Milani S, Marberger M (2004) State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urol 64:1081–1088

    Article  PubMed  Google Scholar 

  4. Jacobsen SJ, Cheetham TC, Haque R, Shi JM, Loo RK (2008) Association between 5-alpha reductase inhibition and risk of hip fracture. JAMA 300:1660–1664

    Article  CAS  PubMed  Google Scholar 

  5. Amory JK, Anawalt BD, Matsumoto AM, Page ST, Bremner WJ, Wang C, Swerdloff RS, Clark RV (2008) The effect of 5alpha-reductase inhibition with dutasteride and finasteride on bone mineral density, serum lipoproteins, hemoglobin, prostate specific antigen and sexual function in healthy young men. J Urol 179:2333–2338

    Article  CAS  PubMed  Google Scholar 

  6. Matzkin H, Chen J, Weisman Y, Goldray D, Pappas F, Jaccard N, Braf Z (1992) Prolonged treatment with finasteride (a 5 alpha-reductase inhibitor) does not affect bone density and metabolism. Clin Endocrinol (Oxf) 37:432–436

    Article  CAS  Google Scholar 

  7. Matsumoto AM, Tenover L, McClung M, Mobley D, Geller J, Sullivan M, Grayhack J, Wessells H, Kadmon D, Flanagan M, Zhang GK, Schmidt J, Taylor AM, Lee M, Waldstreicher J (2002) The long-term effect of specific type II 5alpha-reductase inhibition with finasteride on bone mineral density in men: results of a 4-year placebo controlled trial. J Urol 167:2105–2108

    Article  PubMed  Google Scholar 

  8. Andriole GL, Kirby R (2003) Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia. Eur Urol 44:82–88

    Article  CAS  PubMed  Google Scholar 

  9. Chrischilles E, Rubenstein L, Chao J, Kreder KJ, Gilden D, Shah H (2001) Initiation of nonselective alpha1-antagonist therapy and occurrence of hypotension-related adverse events among men with benign prostatic hyperplasia: a retrospective cohort study. Clin Ther 23:727–743

    Article  CAS  PubMed  Google Scholar 

  10. Dutkiewics S (2001) Efficacy and tolerability of drugs for treatment of benign prostatic hyperplasia. Int Urol Nephrol 32:423–432

    Article  CAS  PubMed  Google Scholar 

  11. Hall GC, McMahon AD (2007) Comparative study of modified release alpha-blocker exposure in elderly patients with fractures. Pharmacoepidemiol Drug Saf 16:901–907

    Article  CAS  PubMed  Google Scholar 

  12. Lee J, Choi NK, Jung SY, Kim YJ, Seong JM, Oh SJ, Park BJ (2009) The risk of fracture with taking alpha blockers for treating benign prostatic hyperplasia. J Prev Med Public Health 42:165–170

    Article  PubMed  Google Scholar 

  13. Souverein PC, Van Staa TP, Egberts ACG, De la Rosette JJMCH, Cooper C, Leufkens HGM (2003) Use of alpha-blockers and the risk of hip/femur fractures. J Intern Med 254:548–554

    Article  CAS  PubMed  Google Scholar 

  14. Wiens M, Etminan M, Gill SS, Takkouche B (2006) Effects of antihypertensive drug treatments on fracture outcomes: a meta-analysis of observational studies. J Intern Med 260:350–362

    Article  CAS  PubMed  Google Scholar 

  15. Takeuchi T, Tsuboi T, Arai M, Togari A (2001) Adrenergic stimulation of osteoclastogenesis mediated by expression of osteoclast differentiation factor in MC3T3-E1 osteoblast-like cells. Biochem Pharmacol 61:579–586

    Article  CAS  PubMed  Google Scholar 

  16. Vestergaard P, Rejnmark L, Mosekilde L (2005) Osteoporosis is markedly underdiagnosed: a nationwide study from Denmark. Osteoporos Int 16:134–141

    Article  PubMed  Google Scholar 

  17. Vestergaard P, Emborg C, Støving R, Hagen C, Mosekilde L, Brixen K (2002) Fractures in patients with anorexia nervosa, bulimia nervosa, and other eating disorders— a nationwide register study. Int J Eat Disord 32:301–308

    Article  PubMed  Google Scholar 

  18. Andersen T, Madsen M, Jørgensen J, Mellemkjær L, Olsen J (1999) The Danish National Hospital Register. Dan Med Bull 46:263–268

    CAS  PubMed  Google Scholar 

  19. Mosbech J, Jørgensen J, Madsen M, Rostgaard K, Thornberg K, Poulsen T (1995) The Danish National Patient Register: evaluation of data quality. Ugeskr Laeger 157:3741–3745

    CAS  PubMed  Google Scholar 

  20. Vestergaard P, Rejnmark L, Mosekilde L (2004) Fracture risk associated with use of anti-epileptic drugs. Epilepsia 45:1330–1337

    Article  CAS  PubMed  Google Scholar 

  21. Charlson M, Pompei P, Ales K, MacKenzie C (1987) A method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 40:373–383

    Article  CAS  PubMed  Google Scholar 

  22. Vestergaard P, Rejnmark L, Mosekilde L (2006) Socioeconomic aspects of fractures within universal public healthcare: a nationwide case-control study from Denmark. Scand J Public Health 34:371–377

    Article  PubMed  Google Scholar 

  23. Kanis J, Johansson H, Johnell O, Oden A, De Laet C, Eisman J, Pols H, Tenenhouse A (2005) Alcohol intake as a risk factor for fracture. Osteoporos Int 16:737–742

    Article  PubMed  Google Scholar 

  24. Klotzbuecher C, Ross P, Landsman P, Abbott T III, Berger M (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the litterature and statistical synthesis. J Bone Miner Res 15:721–739

    Article  CAS  PubMed  Google Scholar 

  25. Munk-Jørgensen P, Mortensen P (1997) The Danish Psychiatric Central Register. Dan Med Bull 44:82–84

    PubMed  Google Scholar 

  26. Vestergaard P, Mosekilde L (2002) Fracture risk in patients with celiac disease, Crohn's disease, and ulcerative colitis: a nation-wide follow-up study in 16,416 patients in Denmark. Am J Epidemiol 156:1–10

    Article  PubMed  Google Scholar 

  27. Strazzullo P, Galletti F, Cirillo M, Siani A, Nunziata V, Giannattasio R, Mancini M (1986) Altered extracellular calcium homoeostasis in essential hypertension: a consequence of abnormal cell calcium handling. Clin Sci (Lond) 71:239–244

    CAS  Google Scholar 

  28. Rejnmark L, Vestergaard P, Mosekilde L (2006) Treatment with beta-blockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: a nationwide case-control study. J Hypertens 24:581–589

    Article  CAS  PubMed  Google Scholar 

  29. Burt VL, Cutler JA, Higgins M, Horan MJ, Labarthe D, Whelton P, Brown C, Roccella EJ (1995) Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960 to 1991. Hypertension 26:60–69

    CAS  PubMed  Google Scholar 

Download references

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark

    P. Vestergaard, L. Rejnmark & L. Mosekilde

  2. The Osteoporosis Clinic, Aarhus University Hospital, Tage Hansens Gade 2, 8000, Aarhus C, Denmark

    P. Vestergaard

Authors
  1. P. Vestergaard
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. Rejnmark
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L. Mosekilde
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P. Vestergaard.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vestergaard, P., Rejnmark, L. & Mosekilde, L. Risk of fractures associated with treatment for benign prostate hyperplasia in men. Osteoporos Int 22, 731–737 (2011). https://doi.org/10.1007/s00198-010-1320-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-010-1320-4

Keywords

Search

Navigation